NCT02130882: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 154 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02130882 |
|---|---|
| Title | A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects With Hypereosinophilic Syndrome (HES) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 19, 2014 |
| Completion date | June 1, 2020 |
| Required reporting date | June 1, 2021, midnight |
| Actual reporting date | Nov. 2, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 154 |